您当前所在的位置:首页 > 产品中心 > 产品信息
Almotriptan_分子结构_CAS_181183-52-8)
点击图片或这里关闭

Almotriptan

产品号 DB00918 公司名称 DrugBank
CAS号 181183-52-8 公司网站 http://www.ualberta.ca/
分子式 C17H25N3O2S 电 话 (780) 492-3111
分子量 335.4643 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 794

产品价格信息

请登录

产品别名

标题
Almotriptan
IUPAC标准名
dimethyl(2-{5-[(pyrrolidine-1-sulfonyl)methyl]-1H-indol-3-yl}ethyl)amine
IUPAC传统名
almotriptan
商标名
Axert
Almogran
别名
almotriptan

产品登记号

CAS号 181183-52-8
PubChem SID 46505165
PubChem CID 123606

产品性质

疏水性(logP) 1.6

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Almotriptan does not prevent migraine attacks.
Indication For the treatment of acute migraine headache in adults
Pharmacology Almotriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Almotriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Almotriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Almotriptan in humans.
Affected Organisms
Humans and other mammals
Half Life 3-4 hours
Protein Binding 35%
Elimination Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.
Distribution * 180 to 200 L
Clearance * 57 L/h [healthy]
* 34.2 L/h [moderate renal impairment (creatinine clearance between 31 and 71 mL/min)]
* 9.8 L/h [severe renal impairment (creatinine clearance between 10 and 30 mL/min)]
External Links
Wikipedia
RxList
Drugs.com

参考文献